Phase 3 Cervical Cancer Trial, Recruiting NCT07168200 Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd Condition: Cervical Cancer
Back to Cervical Cancer

Phase 3 Cervical Cancer Trial, Recruiting

NCT07168200
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing to take part and able to sign a consent form agreeing to join the study.
  • You are able to provide a tissue sample from a primary or secondary (spread) cancer.
  • You have at least one tumor that can be measured on a scan.
  • Your doctor expects you to live for more than 3 months.
  • You are generally well enough to carry out daily activities with little or no limitation (confirm with trial site).
  • Your organs (such as your liver, kidneys, and heart) are working well enough to take part.

Who may not be able to join:

  • Your cancer has spread to lymph nodes or other areas in certain specific parts of the body, as confirmed by a scan or biopsy (confirm with trial site).
  • You have received a live vaccine within the 4 weeks before joining, or plan to receive one during the study.
  • You have taken medication that suppresses your immune system within the 4 weeks before joining.
  • You are currently receiving blood-thinning (anticoagulant) treatment, unless it is a low-dose preventative dose only.
  • You have had another cancer that has not been fully treated or cured within the past 5 years, unless it was a specific type of skin cancer or a very early-stage cancer that was fully cured.
  • You have a known allergy to the study drug or its ingredients, or have had a severe allergic reaction to a similar type of drug (called a monoclonal antibody).
  • You are currently pregnant or breastfeeding.
  • You have any other health condition or circumstance that the study doctor believes could put you at risk or affect the study results.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86-0518-82342973

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Shanghai Shengdi Pharmaceutical Co., Ltd
Registry
ClinicalTrials.gov
Start date
17 October 2025
Est. completion
1 April 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Progression-free survival (PFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov